Current approaches to treatment for HIV-1 infection

Journal of NeuroVirology

Volumn 6, Issue 1 SUPPL., 2000, Pages

  Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Human immunodeficiency virus; Protease inhibitors; Treatment

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

CENTRAL NERVOUS SYSTEM INFECTION; CONFERENCE PAPER; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; PRIORITY JOURNAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

HIV INFECTIONS; HIV-1; HUMANS; NUCLEOSIDES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 0034040562     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. + T cell homeostasis and function in advanced HIV disease. Science 277: 112-116.
2. Barry M, Mulcahy F, Merry C, Gibbons S, Back D (1999). Pharmacokinetics and potential interactions amongst antiretroviral agents used to treat patients with HIV infection. Clin Pharmacokinet 36: 289-304.
3. Baxter JD, Mayers DL, Wentworth DN, Neaton J, Merigan TC (1999). A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in Patients failing antiretroviral treatment [Abstract LB8]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
4. Cameron DW, Heath-Chiozzi M, Danner S, Cohen C, Kravcik S, Maurath C, Sun E, Henry D, Rode R, Potthoff A, Leonard J (1998). Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease. The Advanced HIV Disease Ritonavir Study Group. Lancet 351: 543-549.
5. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM, Katzenstein DA, Montaner JS, Richman DD, Saag MS, Schooley RT, Thompson MA, Vella S, Yeni PG, Volberding PA (1998). Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA 280: 78-86.
6. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58.
7. Centers for Disease control and Prevention (1997). Update: trends in AIDS incidence 1996. MMWR 40: 861-867.
8. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS (1997). Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 94: 13193-13197.
9. + T cells in HIV-1 infected patients receiving highly active anti-retroviral therapy. Nat Med 5: 651-655.
10. Coffin JM (1995). HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267: 483-489.
11. Coombs RW, Welles SL, Hooper C, Reichelderfer PS, D'Aquila RT, Japour AJ, Johnson VA, Kuritzkes DR, Richman DD, Kwok S, Todd J, Jackson JB, DeGruttola V, Crumpacker CA, Kahn J (1996). Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced HIV infection. J Infect Dis 174: 704-712.
12. Cooper DA, Emery S (1999). Latent reservoirs of HIV infection: flushing with IL-2. Nat Med 5: 611-612.
13. Deeks SG, Hellmann NS, Grant RM, Elbeik T, Loftus R, Cohen PT, Grant RM (1999a). Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. J Infect Dis 179: 1375-1381.
14. Deeks SG, Hecht FM, Swanson M et al (1999b). HIV RNA and CD4 Cell Count Response to Protease Inhibitor Therapy in an Urban AIDS Clinic: Response to Both Initial and Salvage Therapy. AIDS 13: F35-F43.
15. DePasquale MP, Kartsonia N, Martinez-Picado J et al (1999). Selection of Protease Resistance Mutations in Semen. [Abstract LB-11]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL.
16. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P (1999). Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353: 2195-2199.
17. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF (1997). Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300.
18. + T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med 5: 512-517.
19. Gulick R, Mellors J, Havlir D, Eron JJ, Gonzalez C, McMahon D, Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chodakewitz JA (1997). Treatment with indinavir, zidovudine and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 337: 734-739.
20. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron Jr JJ, Feinberg JE, Balfour Jr HH, Deyton LR, Chodakewitz JA, Fischl MA (1997). A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 337: 725-732.
21. Havlir DV, Richman DD (1996). Viral dynamics of HIV: Implications for drug development and therapeutic strategies. Ann Intern Med 124: 984-994.
22. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, Ioannidis JP, Holohan MK, Leavitt R, Boone G, Richman DD (1998). Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 339: 1261-1268.
23. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, Hellmann NS, Bandrapalli NI, Digilio L, Branson B, Kahn JO (1998). Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339: 307-311.
24. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, Daley J (1998). Severe premature coronary artery disease with protease inhibitors. Lancet 351: 1328.
25. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vezinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD (1998). Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society-USA Panel. JAMA 279: 1984-1989.
26. Ho DD, Neumann AU, Perelson AS (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
27. Kilby JM, Hopkins S, Venetta TM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS (1998). Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 4: 1302-1307.
28. Kuritzkes DR (1996). Clinical significance of drug resistance in HIV-1 infection. AIDS 10 (Suppl 5): S27-S31.
29. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschol B, Battegay M, Vernazza P, Sudre P, Flepp M, Furrer H, Francioli P, Weber R (1999). Clinical Progression and Virological Failure on Highly Active Antiretroviral Therapy in HIV-1 Patients: a Prospective Cohort Study. Lancet 353: 863-868.
30. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, Ho D (1995). A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 333: 1534-1539.
31. Marschner IC, Collier AC, Coombs RW, D'Aquila RT, DeGruttola V, Fischl MA, Hammer SM, Hughes MD, Johnson VA, Katzenstein DA, Richman DD, Smeaton LM, Spector SA, Saag MS (1998). Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 177: 40-47.
32. Martínez E, Gonget I, Lozano L, Casamitjana R, Gatell JM (1999). Reversion of Metabolic Abnormalities After Switching From HIV-1 Protease Inhibitors to Nevirapine. AIDS 13: 805-810.
33. Mehta S, Moore RD, Graham NM (1997). Potential factors affec-ting adherence with HIV therapy. AIDS 11: 1665-1670.
34. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 126: 946-954.
35. Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, Wainberg MA, Smith D, Robinson P, Hall D, Myers M, Lange JM (1998). A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. Italy, The Netherlands, Canada and Australia Study. JAMA 279: 930-937.
36. Pallela FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998). Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 338: 853-860.
37. Pakker NG, Notermans DW, De Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F, Schellekens PT (1998). Biphasic kinetics of peripheral blood T cells afer triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 4: 208-214.
38. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA, Dellamonica P, Yeni P, Delfraissy JF, Aboulker JP (1998). A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N Engl J Med 339: 1269-1276.
39. Piatak M, Saag MS, Yang LC, Clark SJ, Kappes JC, Luk KC, Hahn BH, Shaw GM, Lifson JD (1993). High levels of HIV-1 in plasma during all stages of infection determined by competitive PCR. Science 259: 1749-1754.
40. Powderly WG, Landay A, Lederman MM (1998). Recovery of the immune system with antiretroviral therapy: The end of opportunism? JAMA 280: 72-77.
41. Raboud JM, Montaner JS, Conway B, Rae S, Reiss P, Vella S, Cooper D, Lange J, Harris M, Wainberg MA, Robinson P, Myers M, Hall D (1998). Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12: 1619-1624.
42. Ruiz L, Bonjoch A, Paredes R, Johnston S, Arno A, Romeu J, Balague M, Sirera G, Tuldra AR, Fumaz C, Clotet B (1999). A multi-center, randomized, open-label comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy [LB-14]. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill.
43. Saag MS, Holodniy M, Kuritzkes DR, O'Brien WA, Coombs R, Poscher ME, Jacobsen DM, Shaw GM, Richman DD, Volberding PA (1996). HIV viral load markers in clinical practice. Nat Med 2: 625-629.
44. Saag MS, Kilby JM (1999). HIV-1 and HAART: a time to cure, a time to kill. Nat Med 5: 609-611.
45. Simpson DM, Tagliati M (1995). Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 9: 153-161.
46. Staszewski S, Miller V, Sabin C, Carlebach A, Berger AM, Weidmann E, Helm EB, Hill A, Phillips A (1999). Virological response to protease inhibitor therapy in an HIV clinic cohort. AIDS 13: 367-373.
47. US Public Health Service (1998). Report of the NIH Panel To Define Principles of Therapy of HIV Infection. Ann Intern Med 128: 1057-1078.
48. Wainberg MA, Friedland G (1998). Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 279: 1977-1983.
49. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonheoffer S, Nowak MA, Hahn BH, Saag MS, Shaw GM (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.
50. Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS (1996). Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. J Infect Dis 174: 696-703.
51. Wit FWNM, van Leeuwen R, Weverling GJ, Jurriaans S, Nauta K, Steingrover R, Schuijtemaker J, Eyssen X, Fortuin D, Weeda M, de Wolf F, Reiss P, Danner SA, Lange JM (1999). Outcome and Predictors of Failure of Highly Active Antiretroviral Therapy: One-Year Follow-up of a Cohort of Human Immunodeficiency Virus Type 1-Infected Persons. J Infect Dis 179: 790-798.
52. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD (1997a). In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 71: 2059-2071.
53. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, Richman DD (1997b). Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295.
54. Yarasheski KE, Tebas P, Sigmund CM, Dagogo-Jack S, Bohrer A, Turk J, Halban PA, Cryer PE, Powderly WG (1999). Insulin resistance in HIV-1 protease inhibitor-associated diabetes. J Acq Immunodefic Synd Hum Retroviruses 29: 209-216.